October 2019

New treatment for Graves Opthalmopathy is a game changer and can prevent long standing proptosis and diplopia in patients with Grave disease.   Graves eye disease occurs because of autoimmune development of TSH receptor antibodies and IgF I receptor antibodies binding to both TSH receptor and  IGF-1 receptors on orbital fibroblast. These orbital fibroblast then […]